Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 4/20 | 0.32 |
| ▸ | HTR2A | P28223 | 3/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6815689 | 0.87 | DPP4 (0.43) | PDE2ALMNATP53HTTDPP4 | |
| SCHEMBL26619829 | 0.87 | DPP4 (0.43) | PDE2ALMNATP53HTTDPP4 | |
| SCHEMBL24295153 | 0.85 | PDE2A (0.36) | PDE2ALMNATP53HTTDPP4 | |
| Hydrochloric Acid SCHEMBL14157379 | 0.85 | IDO1 (0.45) | PDE2ALMNATP53HTTDPP4 | |
| Hydrochloric Acid SCHEMBL14121597 | 0.85 | IDO1 (0.45) | PDE2ALMNATP53HTTDPP4 | |
| SCHEMBL23195508 | 0.85 | NOTUM (0.34) | PDE2ALMNADPP4IDO1 | |
| SCHEMBL30133781 | 0.81 | PDE2A (0.42) | PDE2ADPP4IDO1HTR2CHTR2A | |
| SCHEMBL20832010 | 0.76 | IDO1 (0.40) | PDE2ALMNATP53HTTDPP4 | |
| Hydrochloric Acid SCHEMBL14120522 | 0.74 | IDO1 (0.41) | PDE2ALMNATP53HTTDPP4 | |
| Hydrochloric Acid SCHEMBL14120415 | 0.74 | IDO1 (0.41) | PDE2ALMNATP53HTTDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140275083-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275083-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | IDH1, IDH3B, IDH3A | PDE2A 3092/4885LMNA 4424/4885TP53 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.